Healthcare / Drug Manufacturers - Specialty & GenericStockholm
$23.65
-0.25 (-1.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-77.7M · quality 27.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$698M
P/E
56.3x
↑EV/EBITDA
22.5x
↑ROE
4.7%
↑Gross Margin
37.6%
↓Debt/Equity
1.82
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+18.5%
FCF CAGR
—
FCF margin
-9.0%
FCF / Net income
-3.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $432.7M · net income $12.5M · FCF $-38.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $432.7M | $432.7M | $373.5M | $264.2M | $259.9M |
| Net Income | $12.5M | $12.5M | $43.1M | $22.7M | $30.9M |
| EBITDA | $48.7M | $48.7M | $67.4M | $43.1M | $41.3M |
| EPS | — | — | 1.44 | 0.76 | 1.04 |
| Gross Margin | 37.6% | 37.6% | 41.8% | 43.5% | 44.6% |
| Operating Margin | 11.3% | 11.3% | 18.0% | 12.2% | 15.8% |
| Net Margin | 2.9% | 2.9% | 11.5% | 8.6% | 11.9% |
| Balance Sheet | |||||
| Debt/Equity | 1.82 | 1.82 | 2.06 | 0.68 | 0.43 |
| Current Ratio | 2.84 | 2.84 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-38.9M | $-38.9M | $-270.5M | $-77.7M | $7.1M |
| Returns | |||||
| ROE | 4.7% | 4.7% | 19.5% | 12.8% | 20.0% |
| Valuation | |||||
| P/E | 56.31 | 56.31 | 47.22 | — | — |
| EV/EBITDA | 22.52 | 22.52 | 35.71 | — | — |
| P/B | 2.62 | 2.62 | 9.20 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 15.8% | 15.8% | 41.4% | 1.6% | — |
| EPS Growth | — | — | 89.5% | -26.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-71.9%
Start / end P/E
n/dx → n/dx
EPS bridge
1.44 → n/d
Residual
-71.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.